Mereo BioPharma (MREO) Consolidated Net Income (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Consolidated Net Income of -$6.7 million for Q1 2026, up 47.86% year-on-year from -$4.5 million in Q1 2025, and up 62.18% on a QoQ basis from -$17.8 million in Q4 2025.
Mereo BioPharma (MREO) Consolidated Net Income (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Consolidated Net Income for 4 consecutive years, with -$6.7 million the latest figure, recorded in Q1 2026.
- Quarterly Consolidated Net Income rose 47.86% year-over-year to -$6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$46.1 million (up 20.55% YoY) and the FY2025 annual result came in at -$52.3 million, up 3.37% from the prior year.
- Consolidated Net Income grew to -$6.7 million in Q1 2026 per MREO's latest filing, from -$17.8 million in the prior quarter.
- Over the last five years, Consolidated Net Income for MREO reached as high as -$6.5 million in Q3 2023 and fell as low as -$17.9 million in Q4 2024.
- A 4-year average of -$11.7 million and a median of -$12.2 million in 2023 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2024 — Consolidated Net Income slumped 129.69% — and 2025, when it surged 53.18%.
- Year by year, Consolidated Net Income stood at -$9.1 million in 2023, then slumped by 96.61% to -$17.9 million in 2024, then gained by 0.8% to -$17.8 million in 2025, then jumped by 62.18% to -$6.7 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$6.7 million, -$17.8 million, and -$7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Mereo BioPharma | 242.07 Mn | 242.07 Mn | - | -6.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.72 Mn |
| Dec 31, 2025 | -17.77 Mn |
| Sep 30, 2025 | -7.02 Mn |
| Jun 30, 2025 | -14.62 Mn |
| Mar 31, 2025 | -12.89 Mn |
| Dec 31, 2024 | -17.91 Mn |
| Sep 30, 2024 | -15.00 Mn |
| Jun 30, 2024 | -12.26 Mn |
| Mar 31, 2024 | -8.95 Mn |
| Dec 31, 2023 | -9.11 Mn |
| Sep 30, 2023 | -6.53 Mn |
| Mar 31, 2023 | -12.08 Mn |